Verge Genomics articles

Al Sandrock has landed another post-Biogen gig for this next chapter in his biotech career following the catastrophic collapse of his campaign for Aduhelm.

The R&D expert has lined up a board post for Verge Genomics, an AI-powered startup that has its sights set on a drug program for ALS, followed by new work on Parkinson’s — putting the CNS-focused Sandrock right back into a research arena, where he has fought many, many times before.

Innovation cannot happen in a silo. And this year we have mirrored this need, focusing more than ever before on diversity in management and geography across the biotech world, highlighting a broader range of teams, leaders and science in our Fierce 15 winning companies.

And what a crop we have picked out as the honorees for 2022. Their scientific roots run deep. We have biotechs seeking cures for incurable genetic diseases and companies seeking to tap the latest digital tech in a